Skip to main content
. 2020 Aug 11;14:130. doi: 10.1186/s13256-020-02401-0

Fig. 1.

Fig. 1

Calcemia, bone mineral density, and fracture events for a patient treated with denosumab for 9 years who experienced a rebound effect when treatment was stopped, with a combination of hypercalcemia related to hyperparathyroidism, multiple fractures, and rapid bone loss